The Impact of Integrated Palliative Care on Survival in Idiopathic Pulmonary Fibrosis: A Retrospective Multicenter Comparison.

IF 1.5 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Jenny Lu-Song, Jeffrey A Bakal, Sarah Younus, Onofre Moran-Mendoza, Ingrid Harle, Michelle Morales, Naomi Rippon, Shaney L Barratt, Huzaifa Adamali, Meena Kalluri
{"title":"The Impact of Integrated Palliative Care on Survival in Idiopathic Pulmonary Fibrosis: A Retrospective Multicenter Comparison.","authors":"Jenny Lu-Song, Jeffrey A Bakal, Sarah Younus, Onofre Moran-Mendoza, Ingrid Harle, Michelle Morales, Naomi Rippon, Shaney L Barratt, Huzaifa Adamali, Meena Kalluri","doi":"10.1177/10499091231194722","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Early and integrated palliative care is recommended for patients with idiopathic pulmonary fibrosis. Unfortunately, palliative care delivery remains poor due to various barriers in practice. This study describes various palliative care delivery models in a real-world cohort of patients with idiopathic pulmonary fibrosis, examines the predictors of survival in this cohort of patients, and explores the impact of palliative care on survival. <b>Design:</b> Charts were reviewed retrospectively and analyzed. The primary outcome was survival during a 4-year follow-up period. Two multivariable models were created to examine the impact of therapeutic strategies including palliative intervention on survival. <b>Results:</b> 298 patients with idiopathic pulmonary fibrosis were enrolled from 3 interstitial lung disease clinics with different palliative care models in Edmonton, Canada; Bristol, UK; and Kingston, Canada. 200 (67%) patients received palliative care and 119 (40%) died during follow up. Primary palliative care models (Edmonton and Bristol) delivered palliative care to 96% and 100% respectively compared 21% in the referral model (Queens). Palliative care [adjusted hazard ratio (aHR) .28 (.12-.65)] along with the use of antifibrotics [aHR .56 (.37-.84)], and body mass index >30 [aHR .47 (.37-.85)] reduced the risk of death in our idiopathic pulmonary fibrosis cohort. Opioid use was associated with worse survival [aHR 2.11 (1.30-23.43)]. <b>Conclusions:</b> Both palliative care and antifibrotic use were associated with survival benefit in this cohort of patients with idiopathic pulmonary fibrosis after adjusting for covariates. The benefit was seen despite differences in disease severity and different palliative care delivery models.</p>","PeriodicalId":50810,"journal":{"name":"American Journal of Hospice & Palliative Medicine","volume":" ","pages":"610-618"},"PeriodicalIF":1.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032628/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hospice & Palliative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10499091231194722","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Early and integrated palliative care is recommended for patients with idiopathic pulmonary fibrosis. Unfortunately, palliative care delivery remains poor due to various barriers in practice. This study describes various palliative care delivery models in a real-world cohort of patients with idiopathic pulmonary fibrosis, examines the predictors of survival in this cohort of patients, and explores the impact of palliative care on survival. Design: Charts were reviewed retrospectively and analyzed. The primary outcome was survival during a 4-year follow-up period. Two multivariable models were created to examine the impact of therapeutic strategies including palliative intervention on survival. Results: 298 patients with idiopathic pulmonary fibrosis were enrolled from 3 interstitial lung disease clinics with different palliative care models in Edmonton, Canada; Bristol, UK; and Kingston, Canada. 200 (67%) patients received palliative care and 119 (40%) died during follow up. Primary palliative care models (Edmonton and Bristol) delivered palliative care to 96% and 100% respectively compared 21% in the referral model (Queens). Palliative care [adjusted hazard ratio (aHR) .28 (.12-.65)] along with the use of antifibrotics [aHR .56 (.37-.84)], and body mass index >30 [aHR .47 (.37-.85)] reduced the risk of death in our idiopathic pulmonary fibrosis cohort. Opioid use was associated with worse survival [aHR 2.11 (1.30-23.43)]. Conclusions: Both palliative care and antifibrotic use were associated with survival benefit in this cohort of patients with idiopathic pulmonary fibrosis after adjusting for covariates. The benefit was seen despite differences in disease severity and different palliative care delivery models.

综合姑息治疗对特发性肺纤维化患者生存期的影响:多中心回顾性比较
背景:建议对特发性肺纤维化患者进行早期综合姑息治疗。遗憾的是,由于在实践中存在各种障碍,姑息治疗的实施效果仍然不佳。本研究描述了特发性肺纤维化患者真实世界队列中的各种姑息治疗模式,研究了该队列患者的生存预测因素,并探讨了姑息治疗对生存的影响。设计:回顾性分析病历。主要结果是四年随访期间的存活率。建立了两个多变量模型来研究包括姑息治疗在内的治疗策略对生存期的影响。结果:298 名特发性肺纤维化患者分别来自加拿大埃德蒙顿、英国布里斯托尔和加拿大金斯顿的三家具有不同姑息治疗模式的间质性肺病诊所。200名(67%)患者接受了姑息治疗,119名(40%)患者在随访期间死亡。初级姑息关怀模式(埃德蒙顿和布里斯托尔)分别为96%和100%的患者提供了姑息关怀,而转诊模式(皇后区)仅为21%。姑息治疗[调整后危险比(aHR).28(.12-.65)]、使用抗纤维化药物[aHR.56(.37-.84)]和体重指数大于30[aHR.47(.37-.85)]降低了特发性肺纤维化队列的死亡风险。使用阿片类药物与生存率降低有关[aHR 2.11 (1.30-23.43)]。结论在对共变量进行调整后,姑息治疗和抗纤维化药物的使用与特发性肺纤维化患者队列中的生存获益相关。尽管疾病严重程度不同,姑息治疗的提供模式也不同,但患者仍能从中获益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American Journal of Hospice & Palliative Medicine
American Journal of Hospice & Palliative Medicine HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.80
自引率
5.30%
发文量
169
审稿时长
6-12 weeks
期刊介绍: American Journal of Hospice & Palliative Medicine (AJHPM) is a peer-reviewed journal, published eight times a year. In 30 years of publication, AJHPM has highlighted the interdisciplinary team approach to hospice and palliative medicine as related to the care of the patient and family. This journal is a member of the Committee on Publication Ethics (COPE).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信